Connect with us

M2Gen gets private equity investment

March 18, 2021 - M2Gen, a Tampa company that runs one the world's largest observational research studies in cancer, has new majority ownership. Clayton Dubilier & Rice funds, the Merck Global Health Innovation Fund and McKesson Ventures invested an undisclosed amount to recapitalize M2Gen, a news release said. Existing shareholders Moffitt Cancer Center, Hearst Healthcare and The Ohio State University Foundation continue to hold a significant minority interest M2Gen, according to the release. In conjunction with the recapitalization, Sandra Peterson, operating partner at Clayton Dubilier & Rice, was named chair of the M2Gen board. M2Gen separately announced a new five-year agreement with Merck. Under the terms of the agreement, M2Gen will provide patient-consented, de-identified, linked clinical and genomic data in support of Merck’s oncology efforts.

More Zaps Frontpage

The St. Pete Catalyst

The Catalyst honors its name by aggregating & curating the sparks that propel the St Pete engine.  It is a modern news platform, powered by community sourced content and augmented with directed coverage.  Bring your news, your perspective and your spark to the St Pete Catalyst and take your seat at the table.

Email us: spark@stpetecatalyst.com

Subscribe for Free

Share with friend

Enter the details of the person you want to share this article with.